Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease
- PMID: 15810905
- DOI: 10.1111/j.1601-183X.2005.00124.x
Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative affliction of the elderly, presenting with progressive memory loss and dementia and terminating with death. There have been significant advances in understanding the biology and subsequent diagnosis of AD; however, the furious pace of research has not yet translated into a disease-modifying treatment. While scientific inquiry in AD is largely centered on identifying biological players and pathological mechanisms, the day-to-day realities of AD patients and their caregivers revolve around their steady and heartbreaking cognitive decline. In the past decade, AD research has been fundamentally transformed by the development of genetically modified animal models of amyloid-driven neurodegeneration. These important in vivo models not only replicate some of the hallmark pathology of the disease, such as plaque-like amyloid accumulations and astrocytic inflammation, but also some of the cognitive impairments relevant to AD. In this article, we will provide a detailed review of the behavioral and cognitive deficits present in several transgenic mouse models of AD and discuss their functional changes in response to experimental treatments.
Similar articles
-
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.Eur J Neurosci. 2006 Jan;23(1):251-60. doi: 10.1111/j.1460-9568.2005.04551.x. Eur J Neurosci. 2006. PMID: 16420434
-
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.Neuroscience. 2006 Sep 1;141(3):1149-62. doi: 10.1016/j.neuroscience.2006.05.001. Epub 2006 Jun 6. Neuroscience. 2006. PMID: 16753269
-
Transgenic mouse models of Alzheimer's disease: phenotype and application.Behav Pharmacol. 2003 Sep;14(5-6):419-38. doi: 10.1097/01.fbp.0000088420.18414.ff. Behav Pharmacol. 2003. PMID: 14501255 Review.
-
Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse.J Neurosci Res. 2008 May 15;86(7):1615-25. doi: 10.1002/jnr.21601. J Neurosci Res. 2008. PMID: 18189321
-
A decade of modeling Alzheimer's disease in transgenic mice.Trends Genet. 2006 May;22(5):281-9. doi: 10.1016/j.tig.2006.03.007. Epub 2006 Mar 29. Trends Genet. 2006. PMID: 16567017 Review.
Cited by
-
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.Neurobiol Dis. 2007 Apr;26(1):134-45. doi: 10.1016/j.nbd.2006.12.008. Epub 2006 Dec 20. Neurobiol Dis. 2007. PMID: 17258906 Free PMC article.
-
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.J Neurosci. 2009 Feb 18;29(7):1977-86. doi: 10.1523/JNEUROSCI.2984-08.2009. J Neurosci. 2009. PMID: 19228952 Free PMC article.
-
Analysis of Motor Function in the Tg4-42 Mouse Model of Alzheimer's Disease.Front Behav Neurosci. 2019 May 17;13:107. doi: 10.3389/fnbeh.2019.00107. eCollection 2019. Front Behav Neurosci. 2019. PMID: 31156407 Free PMC article.
-
α7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Aβ effects in a preclinical Alzheimer's mouse model.PLoS One. 2013 Nov 28;8(11):e81828. doi: 10.1371/journal.pone.0081828. eCollection 2013. PLoS One. 2013. PMID: 24312364 Free PMC article.
-
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.Brain. 2011 Jan;134(Pt 1):258-77. doi: 10.1093/brain/awq341. Brain. 2011. PMID: 21186265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
